1060 related articles for article (PubMed ID: 25372935)
1. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
[TBL] [Abstract][Full Text] [Related]
3. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
Harvey RC; James AC; Shields GE
CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
[TBL] [Abstract][Full Text] [Related]
7. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.
Hwang TJ; Lee SM; Sun HJ; Lin HN; Tsai SJ; Lee YC; Chen YS
J Formos Med Assoc; 2003 Jan; 102(1):30-6. PubMed ID: 12684609
[TBL] [Abstract][Full Text] [Related]
8. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
Konarzewska B; Waszkiewicz N; Galińska B; Szulc A
Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867
[TBL] [Abstract][Full Text] [Related]
9. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.
Alvarez E; Ciudad A; Olivares JM; Bousoño M; Gómez JC
J Clin Psychopharmacol; 2006 Jun; 26(3):238-49. PubMed ID: 16702888
[TBL] [Abstract][Full Text] [Related]
10. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
[TBL] [Abstract][Full Text] [Related]
11. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
[TBL] [Abstract][Full Text] [Related]
13. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
[TBL] [Abstract][Full Text] [Related]
14. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
[TBL] [Abstract][Full Text] [Related]
15. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
16. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
17. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms.
Levine SZ; Leucht S
Schizophr Res; 2013 Apr; 145(1-3):125-7. PubMed ID: 23394742
[TBL] [Abstract][Full Text] [Related]
18. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG
Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749
[TBL] [Abstract][Full Text] [Related]
19. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
Leucht S; Pitschel-Walz G; Engel RR; Kissling W
Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
